IP Library Granted Patent US 12,098,220
Granted Patent B2
US 12,098,220 · App. 17/252,564 · Granted Sep 24, 2024

Radiopaque polymers

Inventors: Andrew Lennard Lewis (Farnham, GB); Jasmine Lord (Dronfield, GB)
Assignee: Boston Scientific Medical Device Limited
C08F12/16A61B17/12181A61B17/12186A61K49/0442A61K49/0452C08F12/22C08F112/16C08F112/22C08F116/06C08F212/16C08F212/22C08F16/06C08F16/38C08F116/38C08F216/06C08F216/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,098,220
App. No.
17/252,564
Granted
Sep 24, 2024
Kind
B2
Abstract

A liquid composition comprising a polymer having pendant groups of the formula I: (I) Wherein X is either a bond or is a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N and S; and n is 1 to 4.

Claims (19)

1. A liquid embolic composition suitable for therapeutic embolization, the composition comprising a polymer in solution in an organic solvent, the polymer comprising units of the formula 1:

wherein X is either a bond or is a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N and S;

wherein n is 1 to 4;

wherein the polymer precipitates on contact with normal saline at 20° C.;

wherein the precipitate has a radiodensity of at least 1000HU; and

wherein the polymer is biodegradable.

2. A liquid embolic composition according to claim 1 wherein n is 1, 2 or 3.

3. A liquid embolic composition according to claim 1 wherein the polymer comprises units selected from

4. A liquid embolic composition according to claim 1 where X is selected from a bond, (C 1-4 )alkylene, (C 1-4 )oxyalkylene and amino(C 1-4 )alkylene.

5. A liquid embolic composition according to claim 1 where X is a bond.

6. A liquid embolic composition according to claim 1 wherein the polymer comprises units of the formula 3

7. A liquid embolic composition according to claim 1 comprising the polymer and a water-miscible solvent.

8. A liquid embolic composition according to claim 7 comprising between 3% and 70% wt/wt of the polymer dissolved in the water-miscible solvent.

9. A liquid embolic composition according to claim 7 wherein the water-miscible solvent is a polar aprotic solvent.

10. A liquid embolic composition according to claim 7 wherein the water-miscible solvent is selected from dimethylsulphoxide, dimethylformamide, N, N′-dimethylpropyleneurea, 1,3-dimethyl-2-imidazolidinone, glycerol, ethyl lactate, N-Methyl-2-pyrrolidone and 2-(Oxolan-2-ylmethoxy)ethanol.

11. A liquid embolic composition according to claim 1 wherein n is 2 or 3.

12. A liquid embolic composition according to claim 1 wherein the polymer comprises a polyvinyl alcohol copolymer.

13. A liquid embolic composition according to claim 1 wherein the polymer is non cross linked.

14. A liquid embolic composition according to claim 1 wherein the polymer comprises iodine in an amount of 10% or greater (w/w) based on a dried weight of the polymer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2023
From: BIOCOMPATIBLES UK LIMITED
To: BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED
Reel/Frame 065533/0152 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2021
From: LEWIS, ANDREW LENNARD; LORD, JASMINE
To: BIOCOMPATIBLES UK LTD.
Reel/Frame 055050/0087 →
Priority Claims (1)
GB 1810784 · Jun 29, 2018 · national
Continuity (1)
Related Publication 20210221928A1 · Jul 22, 2021